Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vaxcyte Inc (NQ: PCVX ) 111.29 +0.21 (+0.19%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Vaxcyte Inc < Previous 1 2 3 Next > Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session September 03, 2024 Via Benzinga Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday September 03, 2024 Via Benzinga Peering Into Vaxcyte's Recent Short Interest August 27, 2024 Via Benzinga PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024 May 08, 2024 PCVX stock results show that Vaxcyte beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Recap: Vaxcyte Q4 Earnings February 27, 2024 Via Benzinga Earnings Scheduled For February 27, 2024 February 27, 2024 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. Via Benzinga Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher September 03, 2024 Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's... Via Benzinga Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market September 03, 2024 The company is looking to take on Pfizer in the massive pneumococcal conjugate vaccine market. Via Investor's Business Daily Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says April 10, 2024 The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the... Via Benzinga Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday March 12, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Preview: Vaxcyte's Earnings February 24, 2023 Via Benzinga Expert Ratings for Vaxcyte January 03, 2023 Via Benzinga Why Shares of Vaxcyte Rose 110.7% This Week October 29, 2022 The company released early data for a promising pneumonia vaccine. Via The Motley Fool "Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales January 05, 2024 Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), Via Benzinga Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst December 07, 2023 Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention). Via Benzinga Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names April 20, 2023 Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is... Via Benzinga Why Vaxcyte Stock Is Sliding After Hours April 17, 2023 Vaxcyte Inc (NASDAQ: PCVX) shares are trading lower in Monday's after-hours session after the vaccine company announced the commencement of a Via Benzinga This Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst January 03, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023 April 18, 2023 Via Benzinga Tesla To $205? Here Are 10 Other Price Target Changes For Tuesday January 03, 2023 Goldman Sachs cut Tesla, Inc. (NASDAQ: TSLA) price target from $235 to $205. Goldman Sachs analyst Mark Delaney maintained a Buy rating on the stock. Tesla shares fell 2.6% to $119.93 in pre-market... Via Benzinga Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session April 17, 2023 Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82. Via Benzinga Wingstop, Harley-Davidson, Rollins And Some Other Big Stocks Moving Higher On Wednesday October 26, 2022 U.S. stocks traded mixed, with the Dow Jones gaining more than 200 points on Wednesday. Here are some big stocks recording gains in today’s session. Via Benzinga Earnings Scheduled For February 27, 2023 February 27, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022 December 16, 2022 Via Benzinga Avis Budget, Scholastic And Other Big Gainers From Monday October 25, 2022 U.S. stocks closed higher on Monday, with the Dow Jones gaining over 400 points. Here is the list of some big stocks recording gains in the previous session. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022 December 15, 2022 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022 November 17, 2022 Upgrades Via Benzinga Dow Rises 1.5%; Nasdaq Jumps Over 100 Points October 24, 2022 U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 450 points on Monday. Via Benzinga Why Tricida Shares Dipped Around 95%; Here Are 73 Biggest Movers From Yesterday October 25, 2022 Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) climbed 62.4% to close at $0.39. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation. Via Benzinga Why Vaxcyte Shares Are Trading Sharply Higher? Here Are 63 Stocks Moving In Monday's Mid-Day Session October 24, 2022 Gainers Vaxcyte, Inc. (NASDAQ: PCVX) shares jumped 65% to $33.96 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety,... Via Benzinga < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.